ATNM News and Press, Actinium Pharmaceuticals Inc. From 12/16/21

ATNM came out with excellent BMT engraftment data at ASH. The molecule performs better than standard, non-targeted conditioning regiments both in terms of safety and efficacy. ATNM is trading near 52-week lows. For further details see: Actinium: SIERRA Is Progressing Wel...

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML - High MRD negativity rate compares favorably to 39% MRD negativity rate with CLAG-M alon...

Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting - Data support the advancement to the ...

Actinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting - Consistent 5-times greater dif...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit - Representatives from Actinium's R&D and Clinical Development teams to discuss Actinium's experience developing targeted radiotherapies on panels ...

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...

Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference - Enhanced therapeutic efficacy demonstrated with both Actinium-225 and Lutetium-17...

Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference - Mechanistic synergy via increased cell surface calreticulin expression t...

Actinium Pharmaceuticals (NYSE:ATNM) announces that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia ((r/r AML)) who are fit for intensive therapy has completed the planned dose escalation and patient enro...